NeuroBo Pharmaceuticals (NRBO)
US Market

NeuroBo Pharmaceuticals (NRBO) Income Statement


NeuroBo Pharmaceuticals Income Statement

Last quarter (Q2 2023), NeuroBo Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q2, NeuroBo Pharmaceuticals's net income was $-700.00K. See NeuroBo Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 22Dec 21Dec 20Dec 19Dec 18
Total Revenue
--$ 0.00$ 0.00$ 0.00$ 0.00
Cost of Revenue
Gross Profit
Operating Expense
$ 19.86M$ 19.63M$ 15.30M$ 29.72M$ 20.18M$ 15.49M
Operating Income
$ -19.86M$ -19.63M$ -15.30M$ -29.72M$ -20.18M$ -15.49M
Net Non Operating Interest Income Expense
$ -2.19M$ -2.19M$ 14.00K$ 39.00K$ -22.00K$ -40.00K
Other Income Expense
$ -10.94M$ -7.85M-$ -1.00K$ -1.11M$ -3.00K
Pretax Income
$ -11.13M$ -13.97M$ -15.28M$ -29.68M$ -21.31M$ -15.53M
Tax Provision
$ -26.33M$ -26.33M$ 0.00$ 0.00$ 0.00$ 0.00
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -11.09M$ -13.97M$ -15.28M$ -29.68M$ -21.31M$ -15.53M
Basic EPS
$ -5.28$ -5.43$ -19.80$ -1.83$ -4.08$ -3.65
Diluted EPS
$ -5.28$ -5.43$ -19.80$ -1.83$ -4.08$ -3.65
Basic Average Shares
$ 84.41M$ 2.57M$ 771.46K$ 16.22M$ 5.22M$ 4.25M
Diluted Average Shares
$ 84.41M$ 2.57M$ 888.73K$ 16.22M$ 5.22M$ 4.25M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 19.86M$ 19.63M$ 15.30M$ 29.72M$ 20.18M$ 15.49M
Net Income From Continuing And Discontinued Operation
$ -11.09M$ -13.97M$ -15.28M$ -29.68M$ -21.31M$ -15.53M
Normalized Income
$ -3.11M-$ -15.28M$ -29.68M$ -20.20M$ -15.53M
Interest Expense
-----$ 654.00K
$ -8.93M$ -11.78M$ -15.30M$ -29.72M$ -20.18M$ -15.49M
$ -8.92M$ -11.76M$ -15.25M$ -29.67M$ -20.16M$ -15.49M
Currency in USD

NeuroBo Pharmaceuticals Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis